ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.430
+0.650 (17.20%)
At close: Mar 6, 2026

Revenue by Segment

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Biotechnology
79.54M7.70M5.69M13.81M
Biotechnology Growth
933.61%35.24%-58.79%-
Total
79.54M7.70M5.69M13.81M
Total Growth
933.61%35.24%-58.79%-

Revenue by Geography

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
United States of America
74.01M--
PRC
139.00K386.00K538.00K
PRC Growth
-63.99%-28.25%-
Total
74.15M386.00K538.00K
Total Growth
19109.59%-28.25%-
Source: S&P Global Market Intelligence.